Browse RAB33A

Summary
SymbolRAB33A
NameRAB33A, member RAS oncogene family
Aliases RabS10; Small GTP-binding protein S10; Ras-related protein Rab-33A
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Lipid-anchor Cytoplasmic side
Domain PF00071 Ras family
Function

-

> Gene Ontology
 
Biological Process GO:0000045 autophagosome assembly
GO:0006914 autophagy
GO:0007033 vacuole organization
GO:0010506 regulation of autophagy
GO:0016236 macroautophagy
GO:0016241 regulation of macroautophagy
GO:0019882 antigen processing and presentation
GO:0044088 regulation of vacuole organization
GO:1902115 regulation of organelle assembly
GO:1905037 autophagosome organization
GO:2000785 regulation of autophagosome assembly
Molecular Function GO:0003924 GTPase activity
GO:0005525 GTP binding
GO:0019001 guanyl nucleotide binding
GO:0032561 guanyl ribonucleotide binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-199991: Membrane Trafficking
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-8873719: RAB geranylgeranylation
R-HSA-8854214: TBC/RABGAPs
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolRAB33A
NameRAB33A, member RAS oncogene family
Aliases RabS10; Small GTP-binding protein S10; Ras-related protein Rab-33A
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RAB33A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolRAB33A
NameRAB33A, member RAS oncogene family
Aliases RabS10; Small GTP-binding protein S10; Ras-related protein Rab-33A
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RAB33A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRAB33A
NameRAB33A, member RAS oncogene family
Aliases RabS10; Small GTP-binding protein S10; Ras-related protein Rab-33A
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RAB33A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.70.222
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.2780.198
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2870.751
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-2.180.00102
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.1080.336
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-3.5340.00414
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0090.986
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6490.394
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.6680.393
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9060.229
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3810.72
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2330.116
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RAB33A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRAB33A
NameRAB33A, member RAS oncogene family
Aliases RabS10; Small GTP-binding protein S10; Ras-related protein Rab-33A
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RAB33A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRAB33A
NameRAB33A, member RAS oncogene family
Aliases RabS10; Small GTP-binding protein S10; Ras-related protein Rab-33A
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RAB33A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RAB33A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRAB33A
NameRAB33A, member RAS oncogene family
Aliases RabS10; Small GTP-binding protein S10; Ras-related protein Rab-33A
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RAB33A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRAB33A
NameRAB33A, member RAS oncogene family
Aliases RabS10; Small GTP-binding protein S10; Ras-related protein Rab-33A
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RAB33A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRAB33A
NameRAB33A, member RAS oncogene family
Aliases RabS10; Small GTP-binding protein S10; Ras-related protein Rab-33A
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RAB33A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRAB33A
NameRAB33A, member RAS oncogene family
Aliases RabS10; Small GTP-binding protein S10; Ras-related protein Rab-33A
Chromosomal LocationXq26
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RAB33A collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.